An investor asked on the investor interaction platform: May I ask the Secretary, although Yifan’s revenue declined significantly in the first quarter of 2022, its gross profit was basically the same as that in the first quarter of 2021, but why did the deduction of non profit decline sharply by 30% without reducing the gross profit? Why did the sales expenses increase by 15% in the first quarter when the revenue fell by 20 +%? Why did the tax expenses in the cash flow statement increase by as much as 100% in the first quarter? Please be sure to give a responsible reply to the shareholders. Thank you.
Yifan Pharmaceutical Co.Ltd(002019) ( Yifan Pharmaceutical Co.Ltd(002019) . SZ) said on the investor interaction platform on April 29 that (1) in the first quarter of 2022, the net profit excluding non recurring profits and losses attributable to the shareholders of the listed company decreased by 31.90% compared with the same period of the previous year, mainly due to the centralized purchase of the company’s cooperative products in 2021 and the decline of relevant medical service income, resulting in a year-on-year decrease of 24.53% in operating income; (2) The “taxes paid” in the consolidated cash flow statement in the first quarter of 2022 increased by 114.38% over the same period of the previous year, mainly due to the delayed payment of some taxes according to the policy.
